ADAR1 Capital Management LLC Takes Position in Artiva Biotherapeutics, Inc. $ARTV

Key Points

• ADAR1 Capital Management initiated a position in Artiva Biotherapeutics during the second quarter, purchasing 118,624 shares worth approximately $1.15 million, or about 0.24% of the company. Other institutions, including Blue Owl Capital and BlackRock, also established new stakes.
• Artiva shares opened at $11.77, with a market capitalization of roughly $575 million, after trading between $2.22 and $14.53 over the past year. The company reported quarterly EPS of negative $0.63, matching analyst expectations.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $39, although one firm maintains a sell rating. Insiders have purchased nearly 2 million shares worth about $16.2 million over the past three months.

ADAR1 Capital Management LLC purchased a new position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 118,624 shares of the company's stock, valued at approximately $1,151,000. ADAR1 Capital Management LLC owned approximately 0.24% of Artiva Biotherapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Blue Owl Capital Holdings LP bought a new stake in Artiva Biotherapeutics in the 2nd quarter worth approximately $8,483,000. BlackRock Inc. purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $6,739,000. Citadel Advisors LLC boosted its position in shares of Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company's stock valued at $2,291,000 after acquiring an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company's stock valued at $340,000 after acquiring an additional 117,733 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Artiva Biotherapeutics in the fourth quarter valued at $341,000.

Artiva Biotherapeutics Stock Performance

Artiva Biotherapeutics stock opened at $11.77 on Wednesday. The company has a market capitalization of $575.44 million, a PE ratio of -3.57 and a beta of 2.16. The company has a 50 day moving average price of $10.28 and a 200-day moving average price of $8.36. Artiva Biotherapeutics, Inc. has a fifty-two week low of $2.22 and a fifty-two week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, meeting the consensus estimate of ($0.63). On average, analysts forecast that Artiva Biotherapeutics, Inc. will post -2.62 earnings per share for the current year.

Insider Buying and Selling at Artiva Biotherapeutics

In related news, Director Ra Capital Management, L.P. bought 24,944 shares of the business's stock in a transaction on Friday, July 31st. The shares were bought at an average price of $9.93 per share, for a total transaction of $247,693.92. Following the completion of the purchase, the director directly owned 17,329,570 shares of the company's stock, valued at approximately $172,082,630.10. This trade represents a 0.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders acquired 1,965,251 shares of company stock worth $16,188,035. Corporate insiders own 1.80% of the company's stock.

Wall Street Analyst Weigh In

ARTV has been the subject of a number of analyst reports. HC Wainwright increased their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a "buy" rating in a report on Friday, May 8th. Cantor Fitzgerald reissued an "overweight" rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Needham & Company LLC restated a "buy" rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Finally, Wedbush boosted their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an "outperform" rating in a research report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source